Jane Street
RXRX icon

Jane Street’s Recursion Pharmaceuticals RXRX Stock Holding History

Jane Street’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Sell
199,700
-428,700
-68% -$1.66M ﹤0.01% 7562
2025
Q4 		$2.57M Buy
628,400
+491,300
+358% +$2.43M ﹤0.01% 4345
2025
Q3 		$669K Sell
137,100
-209,100
-60% -$1.1M ﹤0.01% 7210
2025
Q2 		$1.75M Buy
346,200
+55,700
+19% +$274K ﹤0.01% 4633
2025
Q1 		$1.54M Sell
290,500
-20,800
-7% -$152K ﹤0.01% 4807
2024
Q4 		$2.1M Buy
311,300
+210,000
+207% +$1.41M ﹤0.01% 4020
2024
Q3 		$668K Buy
101,300
+35,100
+53% +$252K ﹤0.01% 6668
2024
Q2 		$497K Sell
66,200
-128,000
-66% -$1.12M ﹤0.01% 7036
2024
Q1 		$1.94M Buy
194,200
+159,200
+455% +$1.77M ﹤0.01% 4185
2023
Q4 		$345K Sell
35,000
-40,000
-53% -$285K ﹤0.01% 7406
2023
Q3 		$574K Buy
+75,000
New +$748K ﹤0.01% 6070
2022
Q3 		– Sell
-19,000
Closed -$155K – 10357
2022
Q2 		$155K Buy
+19,000
New +$127K ﹤0.01% 8391

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street's RXRX Position: Q1 2026 in Review

Jane Street sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 125,075 shares — an estimated $483K sold.

Jane Street first reported a position in RXRX in Q4 2021 and held it in 15 quarters. The position peaked at $4.31M in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Jane Street reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 125,075 Recursion Pharmaceuticals shares in Q1 2026, an estimated $483K.
  • Jane Street first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 15 quarters.
  • Jane Street's Recursion Pharmaceuticals position peaked at $4.31M in Q2 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.